Your abstract submission has been received

You have submitted the following abstract to the 2017 ASCO Annual Meeting (June 2-6, 2017). Receipt of this notice does not guarantee that your submission was complete, free of errors, or accepted for presentation. Abstract notifications will be sent to the First Author by April 3, 2017.

Solid organ transplant after treatment for childhood cancer: A report from the Childhood Cancer Survivor Study.

Andrew Charles Dietz, Kristy Seidel, Wendy M. Leisenring, Daniel A. Mulrooney, Jean M. Tersak, Richard D. Glick, Cathy A Burnweit, Daniel M. Green, Lisa Diller, Kevin C. Oeffinger, Susan A Smith, Rebecca M Howell, Marilyn Stovall, Leslie L. Robison, Gregory T. Armstrong, Amanda M. T termuhlen; Children's Hospital Los Angeles, Los Angeles, CA; Fred Hutchinson Cancer Research Center, Seattle, WA; St. Jude Children’s Research Hospital, Memphis, TN; Children’s Hosp of Pittsburgh, Pittsburgh, PA; Steven & Alexandra Cohen Children's Medical Center of New York, New Hyde Park, NY; Nicklaus Children’s Hospital, Miami, FL; Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA; Memorial Sloan Kettering Cancer Center, New York, NY; Department of Radiation Physics, The University of Texas M. D. Anderson Cancer Center, Houston, TX; The University of Texas MD Anderson Cancer Center, Houston, TX

Abstract Text:

Background: Childhood cancer therapy is associated with late onset, organ-specific impairment. However, the prevalence of and outcomes after solid organ transplant (SOT) in childhood cancer survivors (CCS) are unknown. Methods: Data on U.S-based participants in the Childhood Cancer Survivor Study were linked with the Organ Procurement and Transplantation Network. Cumulative incidence of transplant (CIT) 35 years after cancer diagnosis, multivariable Cox regression models for hazard ratios (HR), Kaplan-Meier (KM) survival and corresponding 95% confidence intervals (CI) were estimated. Results: Among 13,318 survivors, median follow-up age 39 years (interquartile range, IQR 33-46), and median time since cancer diagnosis 31 years (IQR 28-36 years), 100 CCS had SOT after study entry with characteristics and outcomes provided (table).

<table>
<thead>
<tr>
<th></th>
<th>Kidney</th>
<th>Heart</th>
<th>Liver</th>
<th>Lung</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of SOT</td>
<td>50†</td>
<td>37</td>
<td>9</td>
<td>7</td>
</tr>
<tr>
<td>Wait List Only</td>
<td>21</td>
<td>25</td>
<td>15</td>
<td>6</td>
</tr>
<tr>
<td>CIT (95% CI)</td>
<td>0.39% (0.27-0.51)</td>
<td>0.30% (0.20-0.40)</td>
<td>0.07% (0.02-0.12)</td>
<td>0.05% (0.01-0.08)</td>
</tr>
<tr>
<td>Wait List or SOT</td>
<td>0.54% (0.40-0.67)</td>
<td>0.49% (0.36-0.62)</td>
<td>0.19% (0.10-0.27)</td>
<td>0.10% (0.04-0.16)</td>
</tr>
<tr>
<td>Median (IQR) Age in years at Cancer Diagnosis</td>
<td>2 (&lt;1-9)</td>
<td>6 (3-11)</td>
<td>6 (4-9)</td>
<td>12 (&lt;1-16)</td>
</tr>
<tr>
<td>Median (IQR) Age in years at SOT</td>
<td>25 (20-35)</td>
<td>28 (21-32)</td>
<td>37 (25-38)</td>
<td>30 (27-37)</td>
</tr>
</tbody>
</table>
### Risk Factors for Nephrectomy Anthracylines SOT or Wait List (HR, 95% CI)*

<table>
<thead>
<tr>
<th>Risk Factor</th>
<th>Nephrectomy</th>
<th>Anthracylines</th>
<th>Actinomycin</th>
<th>Carmustine</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(4.1, 2.2-7.6)</td>
<td>&gt; 0-150 mg/m²</td>
<td>(3.8, 1.3-11.3)</td>
<td>(12.3, 3.1-48.9)</td>
</tr>
<tr>
<td></td>
<td>(22.7, 6.8-75.5)</td>
<td>(8.4, 2.2-32.6)</td>
<td>(5.0, 1.3-19.5)</td>
<td>(6.1, 1.8-20.6)</td>
</tr>
<tr>
<td>Total Body Irradiation</td>
<td>(7.0, 2.3-21.3)</td>
<td>151-300 mg/m²</td>
<td>(15.6, 2.6-92.7)</td>
<td>(19.7, 7.1-54.2)</td>
</tr>
<tr>
<td></td>
<td>(5.0, 1.3-19.5)</td>
<td>(5.0, 1.3-19.5)</td>
<td>(26.5, 9.9-71.0)</td>
<td>(15.6, 2.6-92.7)</td>
</tr>
<tr>
<td>Kidney Radiation</td>
<td>(26.5, 9.9-71.0)</td>
<td>&gt; 450 mg/m²</td>
<td>(94.2, 35.3-251.2)</td>
<td>(15.6, 2.6-92.7)</td>
</tr>
<tr>
<td>&gt; 10-20 Gy</td>
<td>(94.2, 35.3-251.2)</td>
<td>(94.2, 35.3-251.2)</td>
<td>(2.3, 1.1-4.7)</td>
<td>(15.6, 2.6-92.7)</td>
</tr>
<tr>
<td>(2.3, 1.1-4.7)</td>
<td>(2.3, 1.1-4.7)</td>
<td>(2.3, 1.1-4.7)</td>
<td>(2.3, 1.1-4.7)</td>
<td>(15.6, 2.6-92.7)</td>
</tr>
<tr>
<td>&gt; 20 Gy</td>
<td>(94.2, 35.3-251.2)</td>
<td>&gt; 450 mg/m²</td>
<td>(2.3, 1.1-4.7)</td>
<td>(15.6, 2.6-92.7)</td>
</tr>
<tr>
<td>(4.6, 1.1-19.5)</td>
<td>(2.3, 1.1-4.7)</td>
<td>(2.3, 1.1-4.7)</td>
<td>(2.3, 1.1-4.7)</td>
<td>(15.6, 2.6-92.7)</td>
</tr>
<tr>
<td>Heart Radiation</td>
<td>&gt; 20-30 Gy</td>
<td>&gt; 10 Gy</td>
<td>&gt; 30 Gy</td>
<td>&gt; 10 Gy</td>
</tr>
<tr>
<td></td>
<td>(6.1, 1.8-20.6)</td>
<td>&gt; 20-30 Gy</td>
<td>(15.6, 2.6-92.7)</td>
<td>(15.6, 2.6-92.7)</td>
</tr>
<tr>
<td></td>
<td>&gt; 30 Gy</td>
<td>&gt; 20 Gy</td>
<td>(15.6, 2.6-92.7)</td>
<td>(15.6, 2.6-92.7)</td>
</tr>
</tbody>
</table>

Five-Year Survival after SOT (95% CI)

- Nephrectomy: 93.5% (81.0-97.9)
- Anthracylines: 80.6% (63.6-90.3)
- Actinomycin: 27.8% (4.4-59.1)
- Carmustine: 34.3% (4.8-68.6)

†3 patients had different prior SOT, *only HR with p < 0.05 shown. **Conclusions:** Organ-specific radiation and chemotherapy exposure increase the risk for SOT after childhood cancer. Five-year survival rates after renal and cardiac SOT are favorable.
Title:
Solid organ transplant after treatment for childhood cancer: A report from the Childhood Cancer Survivor Study.

Submitter's E-mail Address:
adietz@chla.usc.edu

Is this a late-breaking data submission?
No

Is this abstract a clinical trial?
No

Would like to be considered for a Merit Award?
No

Have the data in this abstract been presented at another major medical meeting?
No

Has this research been submitted for publication in a medical journal?
No

Type of Research:
Cohort Study

Research Category:
Clinical

Continued Trial Accrual:
No

Received Grant funding:
No

Relevant to geriatric oncology:
No

Sponsor:
Andrew Charles Dietz, MD, MS

First Author

Presenting Author
Corresponding Author
Andrew Charles Dietz, MD, MS
Children's Hospital Los Angeles
4650 Sunset Blvd
Los Angeles, CA 90027
Phone Number: 858-966-5811
Email: adietz@chla.usc.edu

Second Author

Kristy Seidel
Fred Hutchinson Cancer Research Center
Seattle, WA 98109

Click to view Conflict of Interest Disclosure

https://asco.confex.com/asco/2017/sci/papers/confirmation.cgi?user...EntryTable=Paper&step=9&StepEntry=535-Paper187290&password=172001
Third Author

Wendy M. Leisenring, ScD
Fred Hutchinson Cancer Research Center
Seattle, WA 98109
Phone Number: 206-667-4374
Email: wleisenr@fhcrc.org

Click to view Conflict of Interest Disclosure

Fourth Author

Daniel A. Mulrooney, MD, MS
St. Jude Children's Research Hospital
MS735
262 Danny Thomas Pl
Memphis, TN 38105
Phone Number: 901-595-5847
Email: daniel.mulrooney@stjude.org

Click to view Conflict of Interest Disclosure

Fifth Author

Jean M. Tersak, MD
Children's Hosp of Pittsburgh
4401 Penn Ave
Pittsburgh, PA 15224
Phone Number: 412-692-5055
Email: jean.tersak@chp.edu

Click to view Conflict of Interest Disclosure

Sixth Author

Richard D. Glick, MD
Steven & Alexandra Cohen Children's Medical Center of New York
269-01 76th Avenue
Suite CH158, Pediatric Surgery
New Hyde Park, NY 11040
Phone Number: 718-470-3636
Email: rglick@nshs.edu

Click to view Conflict of Interest Disclosure

Seventh Author

Cathy A Burnweit, MD
Nicklaus Children's Hospital
Miami, FL
Email: cathy.burnweit@mch.com

Click to view Conflict of Interest Disclosure
Eighth Author
Daniel M. Green, MD
St. Jude Children's Research Hospital
262 Danny Thomas Place
Mail Stop 735
Memphis, TN 38105-2794
Phone Number: 901-595-5915
Fax Number: 901-595-5845
Email: daniel.green@stjude.org

Click to view Conflict of Interest Disclosure

Ninth Author
Lisa Diller, MD
Dana-Farber Cancer Institute and Harvard Medical School
450 Brookline Avenue
Boston, MA 02215
Phone Number: 617-632-5642
Email: lisa_diller@dfci.harvard.edu

Click to view Conflict of Interest Disclosure

Tenth Author
Kevin C. Oeffinger, MD
Memorial Sloan Kettering Cancer Center
New York, NY 10065
Phone Number: 646-888-4731
Email: oeffingk@mskcc.org

Click to view Conflict of Interest Disclosure

Eleventh Author
Susan A Smith, MPH
Department of Radiation Physics, The University of Texas M. D. Anderson Cancer Center
Houston, TX
Email: sasmith@mdanderson.org

Click to view Conflict of Interest Disclosure

Twelfth Author
Rebecca M Howell, PhD
The University of Texas MD Anderson Cancer Center
Houston, TX
Email: rhowell@mdanderson.org

Click to view Conflict of Interest Disclosure

Thirteenth Author
Marilyn Stovall, PhD
Department of Radiation Physics, The University of Texas M. D. Anderson Cancer Center
1515 Holcombe Blvd
Unit 605
Houston, TX 77030
If necessary, you can make changes to your abstract between now and the deadline of Tuesday, February 7, 2017

- To access your submission in the future, use the direct link to your abstract submission from one of the automatic confirmation emails that were sent to you during the submission.
- Or point your browser to /asco/reminder.cgi to have that URL mailed to you again. Your username/password are 187290/172001.

Any changes that you make will be reflected instantly in what is seen by the reviewers. You DO NOT need to go through all of the submission steps in order to change one thing. If you want to change the title, for example, just click "Title" in the abstract control panel and submit the new title.

When you have completed your submission, you may close this browser window.
Tell us what you think of the abstract submission process

Home Page